1. Home
  2. VRCA vs VIVO Comparison

VRCA vs VIVO Comparison

Compare VRCA & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$4.85

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Logo VivoPower PLC Ordinary Shares

VIVO

VivoPower PLC Ordinary Shares

N/A

Current Price

$4.14

Market Cap

80.1M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
VRCA
VIVO
Founded
2013
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
80.1M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
VRCA
VIVO
Price
$4.85
$4.14
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
59.7K
501.4K
Earning Date
05-11-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$94.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
370.22
N/A
52 Week Low
$3.28
$1.97
52 Week High
$9.82
$6.86

Technical Indicators

Market Signals
Indicator
VRCA
VIVO
Relative Strength Index (RSI) 41.65 49.85
Support Level $4.25 $4.20
Resistance Level $6.60 $4.32
Average True Range (ATR) 0.38 0.31
MACD 0.01 0.02
Stochastic Oscillator 20.16 33.58

Price Performance

Historical Comparison
VRCA
VIVO

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About VIVO VivoPower PLC Ordinary Shares

VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.

Share on Social Networks: